Dicot Pharma ABFRA:KN0 -4.96%23 ROA % is -76.15% as of Mar. 2026. GuruFocus rates FRA:KN0 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Dicot Pharma AB ranks worse than 94.42% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Dicot Pharma AB's annualizedNet Income for the quarter that ended in Mar. 2026 was €-5.50 Mil.
Dicot Pharma AB's average Total Assets over the quarter that ended in Mar. 2026 was €7.22 Mil. Therefore, Dicot Pharma AB's annualized ROA % for the quarter that ended in Mar. 2026 was -76.15%.
The historical rank and industry rank for Dicot Pharma AB's ROA % or its related term are showing as below:
FRA:KN0'
s ROA % Range Over the Past 10 Years
Min: -143.88 Med: -111.43 Max: -65.13
Current: -75.3
During the past 9 years, Dicot Pharma AB's highest ROA % was -65.13%. The lowest was -143.88%. And the median was -111.43%.
FRA:KN0's ROA % is ranked worse than 94.42% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs FRA:KN0: -75.30
Dicot Pharma AB (FRA:KN0) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Dicot Pharma AB ROA % Related Terms
Dicot Pharma AB ROA % Historical Data
* Premium members only.
The historical data trend for Dicot Pharma AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's ROA % distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Dicot Pharma AB (FRA:KN0) has a ROA % of -76.15% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Dicot Pharma AB and its competitors. According to the industry distribution chart, Dicot Pharma AB ranks #947 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 94.4%.
Is Dicot Pharma AB's ROA % too high?
Dicot Pharma AB's current ROA % is -76.15%. Based on the distribution chart, Dicot Pharma AB ranks #947 out of 1003 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #947 out of 1003 companies for ROA %. This places Dicot Pharma AB in the lower half of its industry. The industry median ROA % is 2.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current ROA % is -76.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current ROA % of -76.15%. The current ROA % is -76.15%. Dicot Pharma AB's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current ROA % is -76.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
23GF Score
Get the complete analysis for FRA:KN0
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
